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1. 1. Introduction
1.1. Osteoarthritis (OA)
1.1.1. Causes and Symptoms of Osteoarthritis
Osteoarthritis is the most common style of arthritis, and this complicated and chronic degen‐
erative joint disease is extremely found in adults and especially in old people. It mostly affects
the whole joint structures associated with progressive changes in cartilage, menisci, ligaments
and subchondral bone.[1-3] The cartilage covers the end of joint bones and provides slippery
touch during movement, so it is obvious that the degradation of the cartilage extracellular
matrix is a central feature of this disease. Normal articular cartilage makes bones frictionless
with each other, and additionally it can also reduce the damage caused by shock of movement.
[4] However, in osteoarthritis the top layer of articular cartilage wears out and even breaks
down, which initiates the bone rubbing against each other, and therefore causes pain, sclerosis,
swelling and loss of organ function in joint. As time going on, the symptoms are increasing in
frequency and severity, finally the shape of joint changes with deformity, bone spurs may also
occur at the edges of joints, bits of bones even fractures and floats among the joint space.
According to the pre-existing investigations, osteoarthritis has affected the health of a growing
number of people world-widely.[5] Though osteoarthritis will not endanger the life safety of
sufferers, its occurrence and development may not only seriously threaten people's physical
fitness, but also directly reduce their quality of life.
It is well known that the loss of cartilage is concerned with the etiology of osteoarthritis.
[1] The articular cartilage failure is triggered by several correlate factors, such as genetic,
metabolic, and biomechanical factors with secondary components inflammation which react
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mutually.  Until  now  the  pathogenesis  has  not  been  wholly  revealed  due  to  the  multi-
factorial pathological mechanism of osteoarthritis, though many groups have researched for
a long time.[6-10]  Moreover,  other  risk factors  including obesity,  older  age,  joint  injury,
family history, over using, bone density, defect in joint cartilage contribute to osteoarthri‐
tis progression.[11-14]
Based on the above description, it is not hard to see that there must be osteoarthritis syndrome
with a series of heterogeneous presentations,[15] such as a) joint pain, also the major clinical
manifestation; b) joint stiffness, especially morning stiffness; c) functional disorder, like joint
instability and activity limitation. These symptoms of osteoarthritis develop slowly and get
serious increasingly with time.
Osteoarthritis is short of the physical and biochemical integrity of a joint, and also presents as
a mono-arthritis, oligo-arthritis or a poly-arthritis, with several distinct patterns which exist
in most ethnic and racial groups.[16] The common feature of osteoarthritis is characterized by
the early inflammation followed by degeneration of chondrocytes including irreversible
biodegradation. Then osteoarthritis appears as transformation of whole joint structures
including degradation of the articular cartilage, menisci and ligaments, and these are also
accompanied by other performance, such as joint space narrowing (JSN), bone marrow lesions,
synovial inflammation, changes of subchondral bone and generation of osteophytes at the joint
edge (See Figure 1).[2, 10, 13, 17] The degradative process of cartilage is widely considered to
be regulated by the protease involved in osteoarthritis.[4, 6, 10, 18]
Figure 1. Diagrammatic presentation of normal and osteoarthritic joint.[10]
As the major mediators of collagen and proteoglycan cleavage, two classes of proteases are
thought to be responsible for the degradation of cartilage components in osteoarthritis. It was
thought that the collagen degradation is majorly due to the action of matrix metalloproteinase
(MMP) collagenases. Mort et al. have indicated that members of both MMP and ADAMTS (a
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disintegrin and metalloproteinase with thrombospondin motifs) families are important
mediators of the degradation of proteoglycans.[19] At the same time there is evidence for the
role of the cysteine protease cathepsin K in collagen degradation in articular cartilage as
revealed by Konttinen et al..[20] The cleavage of cartilage proteins often occurs at specific sites
on these molecules, resulting in the generation of characteristic N- and C-terminal epitopes
which can be used for the production of antibodies specific for these cleavage products (anti-
neoepitope antibodies).[21] Recent years, Chan et al. have also reported that the increased
chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.[22]
1.2. Importance of osteoarthritis diagnosis and therapy
Currently the total number of osteoarthritis patients in world-wide is more than 600 million.
There are about 1/6 of people in Asia suffering from osteoarthritis at some stage of their life,
among which patients account for 10% of the total population in China, and are increasing in
recent years. It is even estimated that the number may reach to 150 million by 2015. In addition,
it has been reported that a lifetime risk of OA-specific morbidity of about 45% for the knee and
25% for the hip.[23] The National Healthy and Nutrition Examination Survey of USA points
out that the symptoms and signs of clinical osteoarthritis are only in 12% of 6913 people, aged
among from 25 to 74 years, and X-ray results of osteoarthritis appeared in at least one site
occupy 33%.[24] It will be worse that 53% of osteoarthritis patients may lead to disability, loss
of joint function and the ability to work.
Unfortunately, the disease-modifying drugs for osteoarthritis are not available currently, the
drugs have the role of analgesic effect and symptom improvement, but they do not involve
the OA pathology and change the abnormal structure. Even though some styles of drugs can
slow down and reverse the degradation of cartilage, they produce the desired result tardily,
and the curative effect only can maintain for a short period. Osteoarthritis has become the
largest disease causing disability and is known as “no-lethal cancer”, it is so harmful to human
health, and the related research about it has been carried out.[25-27]
While there is no complete cure for OA until now, the early detection followed by efficient
therapy may slow down its detrimental effects. Apparently, a diagnostic system that enables
early and reliable diagnosis of this degenerative joint disease is necessary,[28] such as bio‐
chemical test and imageological diagnosis (X-ray or/and NMR examination). a) biochemical
test: recent years, the special biochemical marker have been drawn attention, hydroxylysyl‐
pyridinoline, heoxylysylpyridinoline, C-reactive protein, Serum amyloid A and so on are all
used to calculate the OA; b) imageological diagnosis: the diagnosis base on radiology mani‐
festation of OA through X-ray or/and NMR examination. However, the imaging technique can
not accurately, selectively evaluate quantitative property of articular cartilage. In addition,
once it is diagnosed as osteoarthritis, the disease has proceeded into the mid- or late- period,
and the opportune moment and prompt treatment to patients are all missed, so the new
technology and strategy need to be further developed. Treatments are also limited to relieve
the symptoms and surgically replace the affected joints. Therefore, to minimize the damage,
understanding the early symptoms of bone disease will help to detect and treat the disease.
The development of bone-related diagnostic and therapeutic programs will be essential,[29]
and a wide range of work in the past years has proved that several proteases might related
directly to osteoarthritis.
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2. Diagnosis of osteoarthritis in targeting specific proteases
2.1. Cathepsin B (Cath B)
As a cysteine proteinase, cathepsin B is a lysosomal cysteine protease, which belongs to the
papain surper-family and has been implicated in the pathology of a number of important
human disease, including cancer and arthritis.[30] It has been shown to be up-regulated in
patients with rheumatoid arthritis,[31] and components of the estracellular matrix are shown
to be substrates for this protease.[32] Cathepsin B is active in aggrecan and cartilage,[33-34]
cleaves the aggrecan G1-G2 domain fragment, and engenders two fragments from the cleavage
at Gly-Val bond to the metalloproteinase cleavage site. For example, Fosang et al. have revealed
that cathepsin B degraded the proteoglycan extensively producing several bands of faster
migration and therefore it can be used as a biomarker of diagnosis of OA.[35]
Then Lai’s group took twelve male nude mice to investigate early diagnosis of osteoarthritis
on a molecular basis, by using the developed cathepsin B sensitive near-infrared (NIR)
fluorescent probe.[36] Firstly, they injected collagenase (1.0%, w/v) into the right knee joint to
induce osteoarthritis and the left knee joint served as a comparison. Secondly, the cathepsin B
sensitive near-infrared fluorescence probe was activated, which could radiate an intensive NIR
fluorescence signal. Finally, the NIR fluorescence signals were caught by an optical imaging
system which could receive an emission wavelength of 680–720 nm. Using this mechanism,
they discovered that 3-fold difference in signal intensity between osteoarthritic and normal
joints can be detected after 24h intravenous injection (see Figure 2). Therefore, it is believed
that cathepsin B activatable NIR fluorescence probe can offer a potential new imaging
technology for early osteoarthritis diagnosis.
Figure 2. Near infrared fluorescence reflectance imaging, which were taken 24 h after intravenous injection of the cath‐
epsin B sensitive auto-quenched probe in a representative animal; (A and B) white light images, (C and D) NIRF im‐
ages.[36]
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2.2. Lactate Dehydrogenase (LDH)
LDH-4 and LDH-5 play an important role in anaerobic metabolism of articular cartilage. In
early 1975, Weseloh and Fiegelmann began to realize the importance of LDH-isoenzym
patterns in human cartilage, and attempted to evaluate it. The result of experience was that
LDH-5 dominates with an average of 75.3%, whereas the LDH-4 (21.7%) and the LDH-3 (3.2%)
were considerably lower, which was significant for the later study. [37]
As we know from previous literatures, degenerative joint diseases were deemed to associate
with increased LDH activity in the synovial fluid. In order to verify the distribution of LDH,
Eveline et al. have made a study to examine healthy and degenerative stifle joints for the goal
of clarifying the origin of LDA in synovial fluid through many technical means, such as
transmission electron microscopy (TEM), immunolabeling and enzyme cytochemistry. And
then all techniques corroborated that the presence of LDH in chondrocytes and in the inter‐
territorial matrix of degenerative stifle joints. Whereas LDH is retained in healthy cartilage
due to permeability limitations, it is released into synovial fluid through abrasion as well as
through unrestricted diffusion as a result of degradation of collagen and increased water
content in degenerative joints.[38]
In addition, the spectrophotometric technique using the pyruvate to lactate conversion was
taken to measure the total LDH activity, while agar gel electrophoresis followed by a tetrazo‐
lium enzymatic staining reaction was used to establish the LDH isoenzyme patterns. Veys et
al. have found long before that the cases of arthritis had high LDH activity both in cellular
material and in cell-free fluid. Moreover, these cases also had an increased percentage of LDH-5
in the cellular extract. It was concluded that the LDH could be a symbol reflecting the degree
of arthritis and used to the diagnosis of early OA.[39]
3. Therapeutics of osteoarthritis in targeting specific proteases
3.1. Sclerostin (SOST)
Sclerostin is a kind of extracellular protease (see Figure 3). As it is well known, the SOST gene
encodes for the secreted protein sclerostin.[40] The expression of SOST in the adult body
exclusively is produced by osteocytes located in bones. Therefore, sclerostin is considered as
negatively modulating osteoblast development and bone formation.[41-42]
At first it was thought that sclerostin might implement its regulatory function via acting as a
modulator of bone morphogenetic proteins (BMPs).[43] Afterwards the accumulating evi‐
dence showed that sclerostin interferes with the Wnt signaling pathway due to binding to the
Wnt co-receptor LRP5 and consequently regulating bone growth.[44-45] SOST restrained the
express of Wnt signaling, which was important in the skeletal development[41, 46] and could
regulate the activity of β-catenin. It was also reported that excess SOST could lead to chon‐
drocyte apoptosis and cartilage damage, namely arthritis, through suppressing the normal
function of β-catenin.[47] At the same time, the study performed by Blom et al. have shown
that superabundant β-catenin would produce a procatabolic effect in the cartilage and promote
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chondrocyte hypertrophy directly related with osteoarthritic pathology. Therefore, moderate
sclerostin would be necessary to keep β-catenin at an appropriate level, and it would be a
crucial indicator in the treatment or diagnosis of osteoarthritis.[48-50] Of note is that, the
importance of Wnt/β-catenin signaling in the pathogenesis of osteoarthritis in humans has not
been well understood. For example, the findings in preclinical studies using anti-sclerostin
therapy in animal models of osteoarthritis have been disappointing, with no reported benefit
on cartilage remodeling during aging or mechanical injury.[50] In addition, the role of
sclerostin in the pathogenesis of osteoarthritis in humans has not yet been well defined, and
the potential utility of treating osteoarthritis with interventions that alter sclerostin is not
known. Still, we are surely pleased to see that summary of SOST in therapeutics of OA will be
performed.
3.2. Matrix Metalloproteinases (MMPs) and Adamalysin with Thrombospondin Motifs
(ADAMTS)
A significant characteristic of osteoarthritis is the degradation of the extracellular cartilage
tissue. According to the previous reports it is widely known that the structural component of
the matrix is mainly composed of collagen and aggrecan, which are regulated by the proteolytic
enzymes, MMPs and ADAMTs.
3.2.1. MMPs
The collagen found primarily in the cartilage ECM is type II collagen, which appears as the
fibrillar network (see Figure 4) and offers strong elasticity to the cartilage matrix. It will be
difficult to be repaired for cartilage once the collagen was lost (see Figure 5).[52-53] Matrix
Figure 3. “Sausage” plot of the averaged minimized structure of murine sclerostin showing the highly flexible regions
of mSOST. Regions colored in blue structurally marked the highly defined areas, regions marked in red are highly dis‐
ordered.[51]
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metalloproteinases (MMP) comprises a family of zinc-dependent enzymes, they are called
collagenases which possess the collagenolytic abilities that degrade extracellular matrix
components.[54] These proteases regulate the initial cleavage of the collagen triple helix,
occurring at 3/4 of the distance from the amino-terminal end of each chain, forming collagen
fragments of 3/4 and 1/4 length.[55] To be directly related to these processes there are three
kinds of collagenases: collagenase-1 or interstitial collagenase (MMP-1); collagenase-2 or
neutrophil collagenase (MMP-8); and collagenase-3 (MMP-13). In addition, MMP-13 is
considered as the primary collagenase in collagen degradation.[6-57] Neuhold et al. showed
that MMP-13 transgenic animals exhibited joint pathology which strongly resembled osteo‐
arthritis. Such a result provided direct evidence in support of a role for this proteinase in the
pathology of this disease.[18]
3.2.2. ADAMTS
Aggrecan is a large proteoglycan including chondroitin sulphate and keratan sulphate
glycosaminoglycan moieties, and is crucial for bringing water to the cartilage matrix which
gives joints the ability to bear the heavy load. Aggrecan plays such a good role, short of it can
lead to the articular cartilage softening and loss of fixed charges, then the joint function will
be reduced and even forfeited.[58] Aggrecan molecules possess two major cleavage sites in the
interglobular domain (IGD) region of the core protein. Without the G1 domain, aggrecan
molecules can be free in and out of the cartilage matrix, leading to the lack of cartilage function.
[59] The first cleavage site at the Asn341-Phe342 bond, creating the neoepitope VDIPEN, is
found to be generated by MMPs.[60] The second site at the Glu373-Ala374 bond, creating the
NITEGE neoepitope, is found to be very important and results from aggrecan cleavage, which
is associated with lots of pathologies.
Figure 4. Electron micrographs of healthy cartilage. a) A dense superficial network of collagen fibers running in paral‐
lel with the articular surface is present. Chondrocytes contain numerous organelles and vesicles. Inset An amorphous
layer (double arrow) extends at the surface. Underneath, densely packed collagen fibers run in parallel with the articular
surface. b) Territorial (A) and interterritorial (B) zones of extracellular matrix are clearly demarcated. Note the large
nucleus and abundance of organelles in the chondrocyte.[38]
Related studies have shown that ADAMTS-5 is a pivotal enzyme for cutting the Glu373~Ala374
bond, and the inhibitors of ADAMTS-5 can debase the aggrecan decomposition effectively. So
ADAMTS-5 is important in osteoarthritis of individuals and responsible for aggrecan degra‐
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dation in normal and diseased cartilage.[61] A new drug, AGG523, in targeting ADAMTS-5
and ADAMTS-4 for therapeutics has entered clinical trials phase I. Studies by Glasson et al.
and Majumdar et al. carried out with ADAMTS-5 knockout and ADAMTS-4/-5 double
knockout mice showed that these animals were more resistant to cartilage degradation after
destabilizing knee surgery.[62-63] However, in human, assumed damaging polymorphisms
in the ADAMTS-5 gene does not show any modification in selectivity to osteoarthritis.[64] The
search for the most important aggrecanase in human osteoarthritis is still going.[65]
3.3. Cathepsin K
Cathepsin K (Cath K) is a cysteine proteinase of papain family. It has been implicated in the
resorption of the bone matrix. Like most of the proteinases, cathepsin K is synthesized and
secreted from the cell as an inactive proenzyme, it should be noted that cathepsin K is secreted
from macrophage and synovial fibroblasts. Cathepsin K cleaves the triple-helical type II
collagen[66], and the special distribution of cathepsin K in osteoarthritic cartilage suggests an
important role of this protease in the etiopathogenesis of osteoarthritis.
Early in 2004, Morko et al. took transgenic mice which were predisposed to early osteoarthritis
because of harboring a short deletion mutation and their non-transgenic litter mates as controls
for study.[53] They used the immunohistochemistry and morphometry to investigate the
distribution of cathepsin K in the knee joints. In the knee joints of transgenic mice, Cathepsin
K was found near sites of matrix destruction in articular chondrocytes, particularly in calcified
cartilaginous matrix and proliferating cells. It indicted that cathepsin K played an important
role in the pathogenesis of osteoarthritis. They also gave an explain that cathepsin K could
digest cartilage matrix components, therefore, it was considered to contribute to the progres‐
sion of osteoarthritic damage. Such studies have provided new clew for the development of
treatments aimed at holding back cartilage degeneration.[53]
Figure 5. Electron micrograph of degenerative cartilage. The amorphous layer is missing, and the articular surface is
uneven. Collagen Wbers are loosely packed and arranged at random. Note amorphous foci in the extracellular matrix
(arrows). (A) Territorial extracellular matrix.[38]
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4. Inhibition of proteases related to OA
There is currently no disease-modifying OA drug available, and treatment is limited to
symptomatic relief or surgical replacement of affected joints. There is thus considerable interest
in developing effective treatments that can halt or reverse the progression of the disease.
4.1. Inhibition of sclerostin
Till date, it is well documented that SOST inhibition is effective for treatment of osteoporo‐
sis.  Tanners group have performed the DNA aptamer selectively against  sclerostin,  and
characterized  DNA  aptamer-sclerostin  binding  affinity.[67]  Aptamers  can  be  used  for
therapeutic purposes and have been investigated in major disease such as osteoarthritis and
osteoporosis.[68]
There are several potential advantages of using aptamers for osteoarthritis and osteoporosis.
Nucleic acids show good pharmacokinetic parameters in cartilage and joints, and many
therapeutic targets tend to be extracellular so that the challenge of cross-membrane delivery
of the nucleic acid can be avoided. Furthermore, aptamers also hold particular promise in
conjunction with other technologies such as fluorescent nanoclusters which open up new
possibilities for diagnostic imaging. At last the stable aptamers display effective and specific
dose-dependent inhibition of sclerostin’s antagonistic effect on Wnt activity. Their studies have
provided an alternative approach to inhibit sclerostin function with therapeutic potential.
However, there is no pre-clinical or clinical evidence to show its efficacy for the treatment of
osteoarthritis. Its role in OA treatment is still under premature. É. Abed et al. explored the role
played by Sirtuin 1 and SOST on the abnormal mineralization and cWnt signaling in human
osteoarthritic subchondral osteoblast (OA Ob). The results indicated that high level of SOST
was responsible, in part for the reduced cWnt and mineralization of human OA Ob, which in
turn is linked with abnormal SIRT1 levels in these pathological cells.[69] A recent study found
that absence of sclerostin in mice with genetic knockout of sclerostin did not alter development
of age-dependent osteoarthritis, and that anti-sclerostin therapy with a monoclonal antibody
in rats with post-traumatic osteoarthritis had no effect on articular cartilage remodeling.[50]
Anyway, antisclerostin therapy has appeared be a promising approach to the treatment of
osteoporosis, while Wnt/β-catenin signaling has also been implicated in the pathogenesis of
osteoarthritis, with the potential for therapeutic intervention yet to be determined.[70]
4.2. Inhibition of MMPs and ADAMTs
According to the reports, it is known that the MMPs can be effectively inhibited by TIMP-1,
-2, -3, -4.[71] Similar to MMPs, ADAMTS family members can also be inhibited effectively by
TIMPs.[72-73] It is illustrated that TIMPs is a significant candidate of blocking cartilage
degradation. And of particular note is that TIMP-3 can inhibit several ADAM/ADAMTS
proteinases, as reported in lots of existed literatures, while TIMP-1 shows ability to inhibit
ADAMTS-10.[72-77] In addition, it is also reported that TIMP-3 can be endocytosed and
degraded by chondrocytes,[78] suggesting that its activity in cartilage may be regulated post-
translationally rather than transcriptionally.[10]
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Wayne et al. have demonstrated that inhibition of full-length ADAMTS-4 by TIMP-3 was
enhanced in the presence of aggrecan, and this interaction was mediated largely through the
binding of aggrecan and the spacer domains of ADAMTS-4 to form a complex with an
improved binding affinity for TIMP-3 over free ADAMTS-4. Therefore, the results also
indicated that the cartilage environment could modulate the function of protease-inhibitor
systems and have relevance for therapeutic approaches to aggrecanase modulation.[79]
ADAMTS-2 is an activity necessary for the formation of extracellular matrix and responsible
for cleaving the N-propeptides of procollagens I–III. Wang et al. have shown that TIMP-3
inhibited ADAMTS-2 in vitro with apparent Ki values of 160 and 602 nM, in the presence of
heparin or without respectively. In a word, TIMP-3 was shown to inhibit procollagen proc‐
essing by cells.[80]
4.3. Inhibition of cathepsin K
Cathepsin K contains a highly conserved catalytic triad Cys25, His159, and Asn175 within its
active site. And in design of the cathepsin K inhibitors, there are several key elements that need
to be considered, its inhibitors must be reversible so as to prevent antigenicity arising from
covalent modification of proteins via irreversible, such as aldehydes, ketones and nitriles.
These reversible inhibitors have become more crucial in recent years because they combine
strongly to the cathepsin K with low reactivity towards cellular nucleophiles.[81] In addition,
the selectivity of inhibitors towards cathepsin K and other cysteine are also desirable to avoid
side effects.[82]
4.3.1. Aldehydes and ketones
Aldehydes and ketones modulate cathepsin K activity via hemiacetal/thiohemiacetal and bond
formation. Some representatives of aldehyde- and ketone-based reversible covalent cathepsin
K inhibitors have reached stages of clinical trials.[83-84]
Since selectivity is important when designing potential drugs to avoid undesired toxicities,
Boros et al. have obtained several of selective aldehyde-based inhibitors[85] and some of them
presented at least 500-fold more potent for cathepsin K than cathepsin B or L. These results
gave the encouragement that the aldehyde-based inhibitors could be developed as an anti-OA
drug in targeting Cath K. In addition, cyclic ketone was also indicated as the inhibitors of the
cysteine protease cathepsin K.
Crystallographic and structure-activity (SA) studies on acyclic ketone-based inhibitors of
cathepsin K have guided the design and identification of two series of cyclic ketone inhibitors.
Marquis et al. have found that the 3-amidopyrrolidin-4-one inhibitors were bound into the
active site of the cathepsin K with two alternate directions. Epimerization issues associated
with the labile alpha-amino ketone diastereomeric center contained within these inhibitor
classes has proven to limit their utility.[86] The results showed that the heterogeneous ketone
inhibitors have different influence on the practical application.
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4.3.2. Nitriles
Inhibitors for papain-like cysteine are derived from peptides, they contains electrophilic group
and have been shown to covalently interact with the thiol group at the active site of cathepsin
K under formation a thioimidate adduct. Among many types of inhibitors, nitriles have
received much attention in recent study.[87-88]
Three chemical classes of nitrile-containing inhibitors of cysteine proteases are known as: a)
cyanamides,[89] b) aromatic nitriles,[90] and c) aza-nitrile derivatives, which includes a P1
aza-amino nitrile.[91-93] Among these inhibitors the aza-nitrile derivatives are the optimal
ones due to the unique properties such as proteolytical stabilization, reversible binding and
excellent inhibitory activity.[94]
In  2013,  Ren  and Yuan et  al.  in  our  research  group has  synthesized  two new series  of
cathepsin K inhibitors. The first series with P2-P3 amide linker have both high selectivity
and  potency,  especially  the  meta-triaryl  compound  13  is  significantly  more  potent  to
cathepsin K (Ki  =  0.0031 nM).  The second series  without  the  P2-P3 amide linkage have
showed a  remarkable  improvements,  the  triaryl  meta-product  13'  possessed  a  favorable
balance between potency (Ki = 0.29 nM) and selectivity of cathepsin K over L, S, B (320-,
1784-,  8566-fold).  Such a  selective  improvement  would be  useful  to  avoid  harmful  side
effects in practical applications of the inhibitors.[94-95]
5. Conclusion and perspective
A significant improvement about scientific cognition of osteoarthritis have been achieved in
the past decades, both the aggrecan and collagen play a supporting role in cartilage. It is
indisputable that there is a close relationship between the component lost and cartilage
degradation, and people are becoming increasingly aware that osteoarthritis is a serious joint
disease which is adjusted by proteases and is performed as the degradation of the cartilage
extracellular matrix. In addition, we also summarized the profoundly reorganizations that risk
factors for OA contain obesity, sports injury, joint instability, particular muscle weakness,
genetic, occupational factors and so on. These are related with mechanical, genetic, metabolic
factors launch and hold the biochemical changes result the joint dysfunction.
As stated above, a wide range of work in the past years has proved that several proteases are
intertwined with osteoarthritis and focused upon in clinical trails. Sclerostin, MMPs,
ADAMTS, cathepsins and LDH have become key targets in the development of the diagnosis
and treatment of osteoarthritis, and significant progress has been made over the decades. It is
no doubt that international co-work in this area will made great progress in the near future
and lead to some effective treatment methods in order to alleviate the symptoms and hamper
the progression of osteoarthritis.
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